Skip to content

Omeros OMER Non Cash Interest Expense On Royalty Obligation

Non Cash Interest Expense On Royalty Obligation at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$13.29M-1.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$39.87M+66.0%
Ardelyx logo
ArdelyxARDX
$1.32M-36.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$7.94M+59.7%
Geron logo
GeronGERN
$3.91M-18.5%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$21M+50.0%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$775.86M+313%
P/S8.6×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept omer:NonCashInterestExpenseOnRoyaltyObligation.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's non cash interest expense on royalty obligation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's non cash interest expense on royalty obligation?
Omeros (OMER) reported non cash interest expense on royalty obligation of -$1.41M in Q1 2026.
How has Omeros's non cash interest expense on royalty obligation changed year-over-year?
Omeros's non cash interest expense on royalty obligation increased by 58.2% year-over-year, from -$3.37M to -$1.41M.
What does non cash interest expense on royalty obligation mean?
Captures the non-cash interest expense accrued on long-term royalty-based financing arrangements. It reflects the effective interest cost associated with future revenue-sharing obligations rather than cash interest payments. This is critical for understanding the true cost of capital embedded in royalty monetization structures.